Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia

NCT05168007 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

342

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: WID-RGC20(Cariprazine) 3mg/day
DRUG: WID-RGC20(Cariprazine) 6mg/day
DRUG: Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day

Sponsor

Whanin Pharmaceutical Company